Unveiling quality of clinical trial in China: from concern to confirmation

Huiyao Huang; Yiru Hou; Hong Fang; Ling Xu; Yue Yu; Huifang Zhang; Jing Zhang; Yu Tang; Gongtao Lan; Wenbao Zhang; Ning Li

doi:10.1002/cac2.12528

PDF

Cancer Communications ›› 2024, Vol. 44 ›› Issue (5) : 576-579. DOI: 10.1002/cac2.12528

NEWS AND VIEWS

Unveiling quality of clinical trial in China: from concern to confirmation

Huiyao Huang¹ ,
Yiru Hou¹^,² ,
Hong Fang¹ ,
Ling Xu³ ,
Yue Yu¹ ,
Huifang Zhang³ ,
Jing Zhang⁴ ,
Yu Tang¹ ,
Gongtao Lan⁵ ,
Wenbao Zhang⁶ ,
Ning Li¹

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Huiyao Huang, Yiru Hou, Hong Fang, Ling Xu, Yue Yu, Huifang Zhang, Jing Zhang, Yu Tang, Gongtao Lan, Wenbao Zhang, Ning Li. Unveiling quality of clinical trial in China: from concern to confirmation. Cancer Communications, 2024, 44(5): 576‒579 https://doi.org/10.1002/cac2.12528

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li N, Huang HY, Wu DW, Yang ZM, Wang J, Wang JS, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019;20(11):e619-e626. CrossRef Google scholar

[2]	Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, et al. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol. 2022;23(11):e515-e520. CrossRef Google scholar

[3]	Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds. BMJ. 2016;355:i5396. CrossRef Google scholar

[4]	Cyranoski D. China cracks down on fake data in drug trials. Nature. 2017;545(7654):275. CrossRef Google scholar

[5]	Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y, et al. Pharmacovigilance in China: Evolution and future challenges. Br J Clin Pharmacol. 2023;89(2):510-522. CrossRef Google scholar

[6]	National Medical Products Administration. Website of ICH work office [2023 08-20]. Available from: https://www.cde.org.cn/ichWeb/index.jsp

[7]	U.S Food and Drug Administration. Dashboards - Compliance Dashboards [2023 08-20]. Available from: https://datadashboard.fda.gov/ora/cd/index.htm

[8]	Ma Y, Wang Q, Duan Y, Shi Q, Zhang X, Yang K, et al. Promoting the quality and transparency of health research in China. J Clin Epidemiol. 2022;152:209-217. CrossRef Google scholar

[9]	Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365-4377. CrossRef Google scholar